Norgestomet and gonadotropin-releasing hormone enhance corpus luteum function and fertility of postpartum suckled beef cows.
In Exp. 1,101 suckled beef cows were administered two injections of prostaglandin F2 alpha (PGF2 alpha) 11 d apart. Cows in Group 1 received no additional treatment. Cows in Groups 2 and 3 received 250 micrograms of GnRH plus 47-h calf removal. Cows in Group 3 also received a norgestomet ear implant that was inserted 4 d after the first PGF2 alpha injection and left in situ for 8 d. The second PGF2 alpha injection was administered approximately 28 h before the time of norgestomet implant removal. The GnRH was administered approximately 30 h after the time of norgestomet implant removal (or 58 h after the second PGF2 alpha injection). Calf removal was the period from the time of implant removal to AI. All cows were artificially inseminated once 75 h after the second PGF2 alpha injection (47 h after implant removal). Reproductive status before the time of GnRH treatment (presynchronization) was determined by multiple sampling (2, 13, and 23 d before GnRH treatment) for blood progesterone concentrations (62% anestrous and 38% cyclic). The GnRH treatment increased (P < .01) the ovulation response and norgestomet reduced (P < .01) the incidence of short luteal phases in the presynchronization anestrous cows. Norgestomet treatment increased (P < .05) the timed breeding pregnancy rates for both presynchronization anestrous and cyclic cows. In Exp. 2, 174 suckled beef cows were administered Syncro-Mate B (which includes norgestomet). Cows in Group 1 received no additional treatment, whereas cows in Group 2 received 250 micrograms of GnRH (30 h after norgestomet implant removal).(ABSTRACT TRUNCATED AT 250 WORDS)
Troxel
T R
TR
Department of Animal Sciences, University of Illinois, Urbana 61801.
Cruz
L C
LC
Ott
R S
RS
Kesler
D J
DJ
D000780:Anestrus / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002214:Capsules; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000494:pharmacology; D004343:Drug Implants; D004973:Estrus Synchronization; D005260:Female; D005298:Fertility / Q000187:drug effects*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary; D007315:Insemination, Artificial / Q000662:veterinary; D010060:Ovulation / Q000187:drug effects; D049590:Postpartum Period / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology; D011897:Random Allocation
D002214:Capsules; D004343:Drug Implants; D011282:Pregnenediones; D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; C100284:norgestomet; D015237:Dinoprost